TR200102436T2 - 5-HT1F agonistleri - Google Patents

5-HT1F agonistleri

Info

Publication number
TR200102436T2
TR200102436T2 TR2001/02436T TR200102436T TR200102436T2 TR 200102436 T2 TR200102436 T2 TR 200102436T2 TR 2001/02436 T TR2001/02436 T TR 2001/02436T TR 200102436 T TR200102436 T TR 200102436T TR 200102436 T2 TR200102436 T2 TR 200102436T2
Authority
TR
Turkey
Prior art keywords
ht1f agonists
ht1f
agonists
vascularization
mammal
Prior art date
Application number
TR2001/02436T
Other languages
English (en)
Inventor
Ann Filla Sandra
Michael Mathes Brian
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200102436T2 publication Critical patent/TR200102436T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bu bulus, bir memelide 4-HT1F reseptörlerinin aktive edilmesinde ve nöron proteininin damar disina sizmasinin inhibe edilmesinde faydali olan, formül (i)'e sahip bir bilesige veya bunun farmasötik bir asit ilave iliskindir.
TR2001/02436T 1999-02-26 2000-02-11 5-HT1F agonistleri TR200102436T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201699P 1999-02-26 1999-02-26

Publications (1)

Publication Number Publication Date
TR200102436T2 true TR200102436T2 (tr) 2002-06-21

Family

ID=22400069

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02436T TR200102436T2 (tr) 1999-02-26 2000-02-11 5-HT1F agonistleri

Country Status (21)

Country Link
EP (1) EP1155020B1 (tr)
JP (1) JP2002537398A (tr)
KR (1) KR20010102355A (tr)
AR (1) AR026856A1 (tr)
AT (1) ATE258935T1 (tr)
AU (1) AU3354000A (tr)
BR (1) BR0008479A (tr)
CA (1) CA2371784A1 (tr)
CO (1) CO5150234A1 (tr)
DE (1) DE60008073T2 (tr)
EA (1) EA200100918A1 (tr)
ES (1) ES2214256T3 (tr)
HU (1) HUP0200245A2 (tr)
ID (1) ID30056A (tr)
IL (1) IL144355A0 (tr)
NO (1) NO20014127D0 (tr)
PE (1) PE20001432A1 (tr)
PL (1) PL350864A1 (tr)
TR (1) TR200102436T2 (tr)
WO (1) WO2000050426A2 (tr)
ZA (1) ZA200106109B (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004094380A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー ５−ｈｔ１ｆアゴニストとしての置換（４−アミノシクロヘキセン−１−イル）フェニルおよび（４−アミノシクロヘキセン−１−イル）ピリジニル化合物
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine

Also Published As

Publication number Publication date
IL144355A0 (en) 2002-05-23
CA2371784A1 (en) 2000-08-31
CO5150234A1 (es) 2002-04-29
KR20010102355A (ko) 2001-11-15
DE60008073T2 (de) 2004-08-05
NO20014127L (no) 2001-08-24
WO2000050426A3 (en) 2000-12-21
ES2214256T3 (es) 2004-09-16
HUP0200245A2 (en) 2002-06-29
ZA200106109B (en) 2002-07-25
EP1155020A2 (en) 2001-11-21
AU3354000A (en) 2000-09-14
PL350864A1 (en) 2003-02-10
EA200100918A1 (ru) 2002-02-28
NO20014127D0 (no) 2001-08-24
ID30056A (id) 2001-11-01
JP2002537398A (ja) 2002-11-05
EP1155020B1 (en) 2004-02-04
ATE258935T1 (de) 2004-02-15
PE20001432A1 (es) 2000-12-18
AR026856A1 (es) 2003-03-05
DE60008073D1 (de) 2004-03-11
BR0008479A (pt) 2002-01-29
WO2000050426A2 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
ATE252572T1 (de) 5-ht1f agonisten
HUP0203939A2 (hu) Gyógyhatású vegyületek és ezeket tartalmazó készítmények és alkalmazásuk
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
ATE236890T1 (de) Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
TR200101899T2 (tr) Trombin inhibitörleri.
TNSN02008A1 (fr) Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant
DK1629849T3 (da) Farmaceutiske sammensætninger indeholdende exendiner og deres agonister
TR200003632T2 (tr) Benzotiyepin-1,1-dioksid türevleri, üretim yöntemi, bunları içeren ilaçlar.
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TR200202806T2 (tr) 4-Triflorometilsulfinilpirazol türevi hazırlama süreci
DE60036924D1 (de) 5-ht1f agonisten
TR200100047T2 (tr) Tiyobenzimidazol türevleri
TR199801419T2 (tr) Sülfone amino asit türevleri ve ayni içerikte metaloproteinez önleyicileri.
TR200200581T2 (tr) İzoflavonları ve bunların benzerlerini içeren bileşimler ve tedavi yöntemleri
PT977741E (pt) Derivados de fenilo substituido, sua preparacao e utilizacao
DE50002364D1 (de) Abgewandelte aminosäureamide als cgrp antagonisten
BR0314096A (pt) Processo para a preparação de uma composição pesticida seca contendo um sal solúvel em água de ácido glifosato e um componente dicarboxilato
TR200102436T2 (tr) 5-HT1F agonistleri
TR200103427T2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
WO2000006173A8 (en) 5-ht1f agonists
TR199902283T2 (tr) Ikame edilmis izokuinolin türevleri ve bunlarin antikonvulsant olarak kullanimi.
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
TR199900719A2 (tr) Fenoksi asetik asit ve fenoksimetil tetrazol türevleri.
TR199902151T2 (tr) Düsük sulu diamin/dikarboksilik asit tuzu.
TNSN04138A1 (fr) Metabolites de l'acide (3-{[4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino] - methyl}-phenoxy)-acetique